After pulling off the rare defeat of an activist investor, DuPont Chief Executive Officer Ellen Kullman has emerged as the new corporate champion of the value of long-term research over short-term profits.
DuPont shareholders last week rejected Nelson Peltz’s bid to join the board with a view to splitting up the 212-year-old chemical maker and slashing costs. His loss was far from certain: Dissidents prevail in most US proxy battles, and Peltz’s firm hadn’t failed since it was founded a decade ago.
“The great example that Ellen provided to all was the courage of her convictions,” said Anne Simpson, director of corporate governance for the California Public Employees’ Retirement System, which voted its 2.64 million shares for DuPont’s slate of directors.
“Too often boards lack backbone and they crumble in the face of pressure.”
In fact, most settle challenges, according to FactSet data, to avoid the scrutiny and distractions that come with proxy fights. And shareholder activists have rarely been busier. DuPont rival Dow Chemical gave board seats to Dan Loeb’s Third Point in November, billionaire Carl Icahn recently pushed EBay to spin off its PayPal unit and Apple bought back shares after pressure from Icahn and others.
When Kullman, also DuPont’s chairman, and the 11 other directors were re-elected, it was her victory. She and the company’s chief financial officer, Nick Fanandakis, crisscrossed the country, meeting with the top 50 investors. And she took her message to individual investors who constitute about one-third of shareholders, many of them retirees who often don’t bother to cast ballots. That may have delivered the margin in what both sides say was a close vote.
Now she’s a role model. “She had a hugely inspirational effect on CEOs to hold their ground,” said Jeffrey A. Sonnenfeld, senior associate dean for leadership studies at the Yale School of Management. “This will be catalytic in terms of corporate governance.”
Kullman, 59, grew up in Wilmington, Delaware, where Dupont is based. A mechanical engineer and the first woman to head the company, she was just out of graduate school in the mid-1980s when Peltz, 72, started doing the deals that made his first fortune. They were leveraged buyouts financed by high-yield bonds sold by Drexel Burnham Lambert’s Michael Milken, an investing style written about in “Barbarians at the Gate.”
Her push-back against Peltz’s break-up argument was that the integration of various businesses – from crop seeds to auto plastics – is key to DuPont’s success. Dismantling the company would weaken the research-and-development engine, the source of DuPont’s future sales.
Kullman deserves credit for standing up for the research program, said Arnold Holtzman, a retired DuPont scientist. He said having access to fundamental research was crucial in his work, which included developing the tiny balloons used to open arteries in coronary angioplasty.
DuPont inventions, from nylon to kevlar, changed lives, and Peltz’s plan threatened the company’s capability to do that in the future, Holtzman, 83, said. “You wouldn’t have the large research and the interaction among the various parts of the company. There wouldn’t be any new initiatives, and certainly not any new science.”
Delaware Governor Jack Markell echoed those sentiments on on his blog, warning before the annual meeting about the activist investor plan to boost earnings with financial maneuvers rather than investing in product development. “This sort of short-term financial engineering is designed to create quick returns – not long-term value for workers, shareholders, and communities.”
After months of criticism, Peltz’s Trian Fund Management nominated four directors for DuPont in January. Kullman made it clear in February she wasn’t going to settle because she wouldn’t accede to Peltz’s insistence he join the board.
The fight went to the wire. Trian employed 175 people on its campaign, while DuPont had 200 making phone calls, mailing information and running websites.
DuPont rose 0.4 percent to close at $70.98 in New York.
Even as she rejected Trian’s call for steep cost cuts and a split, Kullman was making changes to DuPont’s portfolio, selling the auto-paint unit and moving ahead with the spinoff of the commodity-chemicals segment. Shedding those assets will leave DuPont to focus on businesses with steadier earnings, such as agriculture and food ingredients.
“She didn’t make friends doing that,” Yale’s Sonnenfeld said. “But sometimes it’s the people who are closest to the soul of the business that know how to make the changes, separating the barnacles from the boat.”
Kevin Walkush, a fund manager who helps manage $6.7 billion at Jensen Investment Management, said Kullman and her team visited his Oregon offices in February. She helped convince him that Trian’s plan to boost the share price could have “hobbled the company” longer term.
“The strength of her as the leader through this process really came through,” Walkush said. Jensen voted its 1.87 million shares for the DuPont incumbents.
At CalPERS, Simpson said Peltz’s defeat “shows that owners, if they step up and behave like owners, can keep companies anchored in the long term.”
“We don’t want barbarians at the gate,” she added. “We want owners at the gate.”